Chinares Pharma (03320.HK) has announced that its subsidiary, Shanghai Changfu, a wholly-owned subsidiary, has received a Drug Registration Certificate of the low-calcium peritoneal dialysis solution (lactate) product series issued by the National Medical Products Administration and is considered to have passed the consistency evaluation.

This product series is mainly suitable for acute and chronic renal failure patients who require continuous ambulatory peritoneal dialysis due to ineffective non-dialysis treatment. It was initially launched by Baxter of USA in 1992.